Phase
Startup
Xinnate
Xinnate AB develops proprietary peptides for prevention and treatment of wound and topical applications. The lead candidate TCP-25 is part of nature´s own host defense, and the focus is to utilize it’s proven anti-endotoxic properties in functionalized biomaterials and new wound formulations.
Did you know?
The body’s natural defence to promote healing is the secret in Xinnate´s gel.
Accelerated drug development in oncology
Simplify medicine information through digital services
Behavioral coaching app
Antibiotic-free treatment for vaginal bacterial infections
Continuous monitoring of lung function
Individualised information of the intestinal flora
Digital service for patients
Digital tool for meeting an allergy doctor
Mobile systems for movement analysis
Innovative solutions for better health care
Medical device that reduces pain during vein operation
Prebiotics for irritable bowel syndrome
Healthtech for children with eating challenges
Digital health management tool
Nanotechnology based infection control
Therapeutics after stroke
Measuring thyroid hormone levels
Gene editing analysis solution
Stroke detection device
Cost-effective & rapid COVID-19 diagnostic test
Wound treatment gel
